It also effectively treats brain metastases of lung cancer, thanks to its ability to cross the blood-brain barrier.177 Lenvatinib contributes to overcoming sorafenib resistance in HCC with FGFR4 expression.178 Gilteritinib is an FLT3/AXL-TKI that can treat ALK-TKI-resistant NSCLC and AML with FLT internal tandem duplication (ITD).179,180 Entrectinib is a multitargeted TKI that has been recently approved for multiple solid tumors with ROS fusion genes and NTRK1/2/3 fusion genes.181. The gene discussed is ALK; the disease is lung carcinoma.